1068
SOS Twitter instagram Youtube

About Us

  Medanta Institute of Cardiac Sciences & Heart Transplantation brings together a multidisciplinary team of cardiac surgeons and heart failure specialists to offer patients with end-stage heart disease a second chance at life. The program integrates advanced diagnostics, high risk cardiac surgery, mechanical circulatory support, and structured long term rehabilitation under...

Conditions We Treat

Team approach and compassionate care for holistic heart health

Transcatheter aortic valve implantation (TAVI)
Peripheral Angioplasty
Coronary Artery Bypass Graft surgery (CABG)
Aneurysm Repair
Transcatheter aortic valve implantation (TAVI)

TAVI is a surgical procedure performed to replace a blocked or narrowed aortic valve in people who are at greater risk or too sick for open heart surgery. The TAVR(TAVI) procedure involves the implantation of aortic valve without even eliminating the old, damaged valve with the help of a catheter.

Advanced Technology

Artis-Zeego Endovascular Surgical Cath Lab

Artis-Zeego Endovascular Surgical Cath Lab

256 Slice CT

256 Slice CT

3.0 Tesla MRI

3.0 Tesla MRI

Da Vinci Robotic Surgery

Da Vinci Robotic Surgery

Our Specialists

Meet our experienced specialists dedicated to providing comprehensive and personalized care.

Dr. Naresh Trehan

Chairman & Managing Director Book Appointment

Dr. Gagan Gautam

Rheumatology and Immunology Book Appointment

Dr. Rajiv Parakh

Chairman Peripheral Vascular and Endovascular Sciences Book Appointment

Frequently Asked Questions

Waiting time varies depending on blood group, body size, and urgency. Some patients wait weeks; others may wait months.

In symptomatic advance heart failure heart transplant/LVAD is the only treatment possible. Transplant has risks as well as benefits which is assessed during work up and the risk benefit ratio is explained to the family .Overall 1 year Survival rates after transplant -90%.

Mean survival is around 12-14 years. Younger patients with preserved end organs and medication compliance have seen to live 20 years or more also.

Yes. Lifelong immunosuppressive medicines are essential to prevent rejection.

Most patients return to normal daily activities, travel, and even work within months.

It can be permanent (destination therapy) or temporary (bridge to transplant), depending on patient suitability.

In advanced heart failure: Without transplant or LVAD on medications → 1-year survival may be <40% With LVAD → 75–85% survival at 1 year With Transplant → ~90% survival at 1 year So both therapies dramatically improve survival.